By Dr. James W. Stark

A study was recently published in the journal, The Lancet, which examined the use of simvastatin in patients with secondary progressive multiple sclerosis (SPMS). The phase II study enrolled 140 SPMS patients and randomly assigned them to high dose simvastatin (ZocorTM) or a placebo. Importantly, patients were not on MS treatment at the time. The authors report a significant effect of simvastatin on reducing the rate of brain atrophy, as seen on MRI, throughout the entire study period (up to 25 months). A small effect on disability was also noted; although the design of the study was not set up to thoroughly examine disability measures. There were no specific safety issues reported. The researchers are planning a larger study to further examine the effect of ‘statin’ drugs in MS. 

For several years now, a number of studies have looked at the role of ‘statins’ in MS because of their possible anti-inflammatory properties. Results of these studies have been mixed, however, with some showing no benefit and others only mild differences. This current study was well-designed and targeted a specific population and is, therefore, encouraging. Importantly, these medications are not completely without potential for adverse events and, at this time, the IMSMP is not advocating for widespread use of ‘statins’ in our patients. Patients are encouraged to discuss this with their physician at their next office visit.